{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=58&state=Michigan", "query": { "state": "Michigan", "city": "Detroit", "page": 58 }, "page_size": 10 }, "pagination": { "page": 58, "page_size": 10, "total_count": 7248, "total_pages": 725, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=59&state=Michigan&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Detroit&page=57&state=Michigan&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T01:23:21.095Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01273493", "title": "A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Metastases", "Hepatic Insufficiency" ], "interventions": [ { "name": "Trabectedin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2010-12", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2016-02-15", "last_synced_at": "2026-11-15T01:23:21.095Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Detroit, Michigan • New York, New York + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01273493" }, { "nct_id": "NCT07213804", "title": "A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Neoplasms", "Fallopian Tube Neoplasms", "Peritoneal Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Sofetabart Mipitecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" }, { "name": "MIRV", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1630, "start_date": "2025-10-22", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-15T01:23:21.095Z", "location_count": 85, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07213804" }, { "nct_id": "NCT01785849", "title": "Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyperparathyroidism, Secondary" ], "interventions": [ { "name": "Etelcalcetide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 508, "start_date": "2013-03-12", "completion_date": "2014-06-12", "has_results": true, "last_update_posted_date": "2019-08-26", "last_synced_at": "2026-11-15T01:23:21.095Z", "location_count": 51, "location_summary": "Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Azusa", "state": "California" }, { "city": "Covina", "state": "California" }, { "city": "Lakewood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01785849" }, { "nct_id": "NCT02639338", "title": "Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "SOF/VEL/VOX", "type": "DRUG" }, { "name": "SOF/VEL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2015-12-23", "completion_date": "2017-01-02", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-11-15T01:23:21.095Z", "location_count": 30, "location_summary": "Long Beach, California • Los Angeles, California • Palo Alto, California + 27 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Rialto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02639338" }, { "nct_id": "NCT02145078", "title": "Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2014-06", "completion_date": "2017-03-07", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-11-15T01:23:21.095Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02145078" }, { "nct_id": "NCT04624685", "title": "iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Glaucoma, Open-Angle" ], "interventions": [], "intervention_types": [], "sponsor": "Glaukos Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 475, "start_date": "2020-01-15", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2021-10-20", "last_synced_at": "2026-11-15T01:23:21.095Z", "location_count": 24, "location_summary": "Glendale, Arizona • Fayetteville, Arkansas • Santa Rosa, California + 20 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Cape Coral", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04624685" }, { "nct_id": "NCT01146925", "title": "Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Contrast-Induced Acute Kidney Injury" ], "interventions": [ { "name": "CRMD-001-Deferiprone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CorMedix Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2010-06", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2011-06-27", "last_synced_at": "2026-11-15T01:23:21.095Z", "location_count": 8, "location_summary": "Indianapolis, Indiana • Detroit, Michigan • Petoskey, Michigan + 5 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Petoskey", "state": "Michigan" }, { "city": "Southfield", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01146925" }, { "nct_id": "NCT01137968", "title": "Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "imetelstat", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Geron Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2010-05", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2016-01-26", "last_synced_at": "2026-11-15T01:23:21.095Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01137968" }, { "nct_id": "NCT01903993", "title": "A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \"POPLAR\"", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 287, "start_date": "2013-08-06", "completion_date": "2018-09-06", "has_results": true, "last_update_posted_date": "2019-10-02", "last_synced_at": "2026-11-15T01:23:21.095Z", "location_count": 29, "location_summary": "Tucson, Arizona • Hot Springs, Arkansas • Loma Linda, California + 26 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Vallejo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01903993" }, { "nct_id": "NCT06496178", "title": "A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Petosemtamab", "type": "DRUG" }, { "name": "Investigator's Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 621, "start_date": "2024-06-25", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T01:23:21.095Z", "location_count": 59, "location_summary": "Mobile, Alabama • Prescott, Arizona • Scottsdale, Arizona + 51 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Prescott", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06496178" } ] }